Related Experiment Video
Updated: Aug 17, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Not all viruses are bad guys: the case for reovirus in cancer therapy
Kara L Norman1, Patrick W K Lee
1Cancer Biology Research Group, and Department of Microbiology and Infectious Diseases, Faculty of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1, Canada.
Abstract:
Efforts to improve on cancer therapy have begun to capitalize on recent advances in our understanding of tumorigenesis. Tumor-specific characteristics are being exploited to develop selective antibodies and pharmacological inhibitors that specifically target cancer cells, and these agents are already showing clinical promise. None of these approaches, however, has captured our imagination as much as the use of replication-competent viruses to kill cancer cells. Whereas normal cells resist replication, tumor cells have an impaired antiviral response that sensitizes them to oncolytic viruses. One such virus is reovirus, a benign, naturally occurring virus that can effect tumor regression in animal models. Reovirus is demonstrating much promise in pre-clinical studies of cancer therapy and in clinical trials, where a lack of toxicity and signs of efficacy are generating excitement for this novel potential cancer therapeutic.
Insights
Replication-competent viruses, like reovirus, show promise in cancer therapy by selectively targeting tumor cells. These oncolytic viruses exploit cancer cells
Area of Science:
- Oncology and Virology
Background:
- Cancer therapy research is advancing through understanding tumorigenesis.
- Targeted therapies like antibodies and inhibitors show clinical promise.
- Oncolytic viruses represent a novel therapeutic strategy.
Purpose of the Study:
- To explore the potential of replication-competent viruses as cancer therapeutics.
- To highlight reovirus as a promising oncolytic virus for cancer treatment.
Main Methods:
- Exploiting tumor-specific characteristics for targeted therapy development.
- Utilizing reovirus, a naturally occurring benign virus, for cancer treatment.
- Evaluating reovirus in pre-clinical studies and clinical trials.
Main Results:
- Tumor cells are more susceptible to oncolytic viruses than normal cells due to impaired antiviral responses.
- Reovirus has demonstrated the ability to effect tumor regression in animal models.
- Reovirus shows a lack of toxicity and signs of efficacy in clinical trials.
Conclusions:
- Replication-competent viruses, particularly reovirus, offer a novel and exciting approach to cancer therapy.
- Reovirus demonstrates significant promise as a potential cancer therapeutic agent with a favorable safety profile.
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Mechanisms of Retrovirus-induced Cancers
Mechanisms of Retrovirus-induced Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

